Functional Concept
RFK Jr. Reshuffles Top HHS Leadership, Replacing Chief of Staff and Deputy Chief
RFK Jr.; HHS; leadership shakeup; chief of staff; Heather Flick Melanson; Hannah Anderson; Matt Buckham; staff changes; federal health policy
RFK Jr. Fires Top Deputies, Reshuffles Leadership at HHS
Robert F. Kennedy Jr.; Health and Human Services; leadership reshuffle; chief of staff; personnel changes; Matt Buckham; Trump loyalists; Heather Flick Melanson; Hannah Anderson
RFK Jr. Reshuffles Top HHS Leadership, Names New Acting Chief of Staff
RFK Jr.; HHS; leadership shakeup; chief of staff; personnel changes; Matt Buckham; Heather Flick Melanson; Hannah Anderson; health policy; Department of Health and Human Services
RFK Jr. Reshuffles Top Leadership at HHS, Replaces Chief of Staff and Deputy Policy Chief
RFK Jr.; HHS leadership shakeup; chief of staff replaced; Heather Flick Melanson; Hannah Anderson; Matt Buckham; personnel changes; Make America Healthy Again
Outsmarting Data Bottlenecks in Pharma: The Clinical Terminology Advantage
data bottlenecks; clinical terminology; pharmaceutical industry; data integration; interoperability; regulatory compliance; AI in pharma; patient outcomes
GSK’s ViiV Expands Licensing Deal to Increase Access to Long-Acting Injectable HIV Treatment
GSK; ViiV Healthcare; long-acting HIV treatment; cabotegravir; licensing agreement; Medicines Patent Pool; generic manufacturing; HIV; global health
Biopharma Layoffs Continue to Surge in First Half of 2025
biopharma; layoffs; 2025; workforce reductions; industry trends; biotech closures; year-over-year increase
ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals
ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development
Novavax Approval Process Raises Concerns Among Former Regulators About FDA Integrity
Novavax; FDA approval; COVID-19 vaccine; regulatory process; integrity concerns; delays; political interference
Vor Bio’s $4B+ Revival Deal for RemeGen’s Autoimmune Drug Triggers Divergent Stock Moves
Vor Bio; RemeGen; telitacicept; autoimmune disease; $4 billion deal; myasthenia gravis; stock reaction; CEO change; PIPE financing